These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 20591031)

  • 1. The CARI guidelines. Cost-effectiveness and socioeconomic implications of prevention and management of chronic kidney disease in type 2 diabetes.
    Chadban S; Howell M; Twigg S; Thomas M; Jerums G; Cass A; Campbell D; Nicholls K; Tong A; Mangos G; Stack A; MacIsaac RJ; Girgis S; Colagiuri R; Colagiuri S; Craig J;
    Nephrology (Carlton); 2010 Apr; 15 Suppl 1():S195-203. PubMed ID: 20591031
    [No Abstract]   [Full Text] [Related]  

  • 2. The CARI guidelines. Prevention and management of chronic kidney disease in type 2 diabetes.
    Chadban S; Howell M; Twigg S; Thomas M; Jerums G; Cass A; Campbell D; Nicholls K; Tong A; Mangos G; Stack A; MacIsaac RJ; Girgis S; Colagiuri R; Colagiuri S; Craig J;
    Nephrology (Carlton); 2010 Apr; 15 Suppl 1():S162-94. PubMed ID: 20591029
    [No Abstract]   [Full Text] [Related]  

  • 3. ACE inhibitors as a shield against diabetic nephropathy.
    Materson BJ
    Arch Intern Med; 1996 Feb; 156(3):239-40. PubMed ID: 8572832
    [No Abstract]   [Full Text] [Related]  

  • 4. Best practice for hypertensive patients with kidney disease.
    de Zeeuw D
    Hosp Med; 2003 Feb; 64(2):96-100. PubMed ID: 12619337
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nephropathy in patients with type 2 diabetes mellitus.
    Ritz E; Orth SR
    N Engl J Med; 1999 Oct; 341(15):1127-33. PubMed ID: 10511612
    [No Abstract]   [Full Text] [Related]  

  • 6. ACE inhibitors and renoprotection.
    Peterson K
    J Fam Pract; 1996 May; 42(5):453. PubMed ID: 8642355
    [No Abstract]   [Full Text] [Related]  

  • 7. [Can progression to terminal renal insufficiency be avoided in diabetic nephropathy?].
    Luño J; Valderrábano F
    An Med Interna; 1998 Nov; 15(11):567-71. PubMed ID: 9882851
    [No Abstract]   [Full Text] [Related]  

  • 8. Renoprotection in diabetes: genetic and non-genetic risk factors and treatment.
    Parving HH
    Diabetologia; 1998 Jul; 41(7):745-59. PubMed ID: 9686914
    [No Abstract]   [Full Text] [Related]  

  • 9. Is renoprotection with RAAS blockade a failed paradigm? Have we learnt any lessons so far?
    Onuigbo MA
    Int J Clin Pract; 2010 Sep; 64(10):1341-6. PubMed ID: 20716141
    [No Abstract]   [Full Text] [Related]  

  • 10. Normalization of kidney dysfunction in normotensive, normo-albuminuric type 2 diabetes.
    Futrakul N; Futrakul P
    Ren Fail; 2013 Aug; 35(7):1058-9. PubMed ID: 23859540
    [No Abstract]   [Full Text] [Related]  

  • 11. Diabetic nephropathy and renal protective agents.
    Marchiando R; Elston MP
    S D J Med; 1999 Oct; 52(10):385-6. PubMed ID: 10546516
    [No Abstract]   [Full Text] [Related]  

  • 12. Angiotensin-receptor blockade in renal disease: the hard issues.
    Sica DA
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):469-71. PubMed ID: 15225107
    [No Abstract]   [Full Text] [Related]  

  • 13. [Diabetic nephropathy--manage now!].
    Ritz E
    Dtsch Med Wochenschr; 2010 Mar; 135(9):p8. PubMed ID: 20200822
    [No Abstract]   [Full Text] [Related]  

  • 14. Cost-effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in newly diagnosed type 2 diabetes in Germany.
    Adarkwah CC; Gandjour A
    Int J Technol Assess Health Care; 2010 Jan; 26(1):62-70. PubMed ID: 20059782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Practical problems in the management of hypertension in the diabetic patient.
    O'Hare JP
    J Diabetes Complications; 1996; 10(3):146-8. PubMed ID: 8807462
    [No Abstract]   [Full Text] [Related]  

  • 16. To pay or not to pay? A decision and cost-utility analysis of angiotensin-converting-enzyme inhibitor therapy for diabetic nephropathy.
    Clark WF; Churchill DN; Forwell L; Macdonald G; Foster S
    CMAJ; 2000 Jan; 162(2):195-8. PubMed ID: 10674051
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [ACE inhibitors and AT-II antagonists--do they protect against renal disease?].
    Rossing P; Parving HH
    Ugeskr Laeger; 2006 Apr; 168(15):1564; author reply1564-5. PubMed ID: 16640990
    [No Abstract]   [Full Text] [Related]  

  • 18. Diabetic kidney disease: act now or pay later.
    Atkins RC; Zimmet P
    J Hypertens; 2010 Feb; 28(2):408-10. PubMed ID: 20087106
    [No Abstract]   [Full Text] [Related]  

  • 19. Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.
    Crook ED; Preddie DC
    Ethn Dis; 2002; 12(4):S3-49-52. PubMed ID: 12477155
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preserving the diabetic kidney.
    Poirier SJ
    J Fam Pract; 1998 Jan; 46(1):21-7. PubMed ID: 9451365
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.